GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
DescriptionThis phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795 (GSK2141795) when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Akt inhibitor GSK2141795, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Akt inhibitor GSK2141795 with dabrafenib and trametinib may be a better treatment for cancer.
Inclusion and Exclusion Criteria
Please contact Carryl Du Bois to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Please contact Carryl Du Bois to learn more about where you can participate in this trial. Please use the contact form on the right side.